• Burmese
Saturday, July 12, 2025
No Result
View All Result
NEWSLETTER
The Irrawaddy
25 °c
Yangon
  • Home
  • News
    • Burma
    • Politics
    • World
    • Asia
    • Myanmar’s Crisis & the World
    • Ethnic Issues
    • War Against the Junta
    • Junta Cronies
    • Conflicts In Numbers
    • Junta Watch
    • Fact Check
    • Investigation
    • Myanmar-China Watch
    • Obituaries
  • Politics
  • Business
  • Opinion
    • Commentary
    • Guest Column
    • Analysis
    • Editorial
    • Stories That Shaped Us
    • Letters
  • Junta Watch
  • Ethnic Issues
  • War Against the Junta
  • In Person
    • Interview
    • Profile
  • Books
  • Donation
  • Home
  • News
    • Burma
    • Politics
    • World
    • Asia
    • Myanmar’s Crisis & the World
    • Ethnic Issues
    • War Against the Junta
    • Junta Cronies
    • Conflicts In Numbers
    • Junta Watch
    • Fact Check
    • Investigation
    • Myanmar-China Watch
    • Obituaries
  • Politics
  • Business
  • Opinion
    • Commentary
    • Guest Column
    • Analysis
    • Editorial
    • Stories That Shaped Us
    • Letters
  • Junta Watch
  • Ethnic Issues
  • War Against the Junta
  • In Person
    • Interview
    • Profile
  • Books
  • Donation
No Result
View All Result
The Irrawaddy
No Result
View All Result
Home News Asia

India’s Rejection of Drug Patent Could Reverberate

Linda A. Johnson by Linda A. Johnson
April 2, 2013
in Uncategorized
Reading Time: 3 mins read
0 0
A A
India's Rejection of Drug Patent Could Reverberate

A patient holds medicine last year at Rajiv Gandhi Government General Hospital in Chennai

2.3k
VIEWS
Share on FacebookShare on Twitter

The India Supreme Court’s rejection of a patent for an improved version of a costly cancer drug by Novartis AG could have big implications for the world’s largest drugmakers.

The ruling, which was handed down on Monday, signals the latest shift in the world of drug development in emerging markets such as India and Brazil, where drugmakers have been looking for growth.

Western governments routinely grant patents for slightly improved versions of medicines whose patents are about to expire. That enables drugmakers to get many patients to upgrade to their new, generally more expensive versions rather than the cheaper, generic knockoffs even though some doctors and patients argue that the improvements don’t justify the high cost.

RelatedPosts

Anti-Coup Icon Explains Urgent Call for NUG Reform

Anti-Coup Icon Explains Urgent Call for NUG Reform

July 11, 2025
87
Myanmar Junta Chief Thanks Trump for Shutting Down VOA and RFA

Myanmar Junta Chief Thanks Trump for Shutting Down VOA and RFA

July 11, 2025
353
KIA Denies Rumor Chief Under House Arrest in China

KIA Denies Rumor Chief Under House Arrest in China

July 11, 2025
304

But India, Indonesia and some other developing countries have been bucking that trend. They’ve been shooting down Western patents and licensing local pharmaceutical companies to make cheap generic versions of medicines that most of their residents otherwise could not afford.

Major drugmakers such as Pfizer and Bayer AG on Monday declined to say what they might do regarding the ruling and other recent decisions by poor countries to let local drugmakers sell cheap generic versions for medicines that have monopolies under patents in Western countries. But some industry insiders—including a Novartis executive—predict that multinational drugmakers will decide against doing drug research and development in India.

“Novartis will not invest in drug research in India. Not only Novartis, I don’t think any global company is planning to research in India,” Ranjit Shahani, the vice chairman and managing director of Novartis India, said after the ruling.

Erik Gordon, a professor and analyst at University of Michigan’s Ross School of Business, agrees. He said the ruling means that there’s “no reason to do research and development in India” because of its “national policy of hostility toward medicine patents.”

One thing is clear, though: Emerging markets are not the gold mine that optimistic pharmaceutical executives have been making them out to be.

India’s move casts significant doubt on the companies’ predictions that within a few years, emerging markets will generate one-quarter or even one-third of their global revenue. They’ve been counting on governments and a rising middle class in emerging markets to spend more on their brand-name medicines rather than the locally made drugs that may be counterfeit.

“Less patent protection in huge, developing markets means less revenue, and growth stories that are going to look like fantasies,” Gordon said.

That’s a big problem for drugmakers that already squeezed on all sides.

Government and private health plans in industrialized countries, particularly in deficit-laden Europe, have been pushing for lower drug prices and occasionally even refusing to cover very-expensive drugs. Consumer health spending has been constrained by severe recessions across the globe. Research is ever more expensive. And virtually every drugmaker has been hurt in the last few years by expirations of patents for popular drugs that once made billions every year.

Countries such as Indonesia and Brazil for several years have been licensing local pharmaceutical companies to make cheap generic versions of medicines, usually drugs for HIV, the deadly virus that causes AIDS.

But recently, India has overturned patents for several cancer drugs, including Bayer AG’s Nexavar, AstraZeneca PLC’s Iressa, Pfizer Inc.’s Sutent and Bristol-Myers Squibb Co’s Sprycel, according to Mark Grayson, spokesman for the big drugmakers’ trade group, Pharmaceutical Research and Manufacturers of America.

“Certainly companies will take this into account in deciding … whether India’s a good market,” he said.

Grayson noted India has granted patents for very few medicines. He and the trade group’s members say that without patents to protect sales of their drugs, drug companies won’t have the billions they need to develop innovative new drugs.

“This is really about the future and coming up with medicines for unmet medical needs,” he said.

Meanwhile, last month Pfizer’s chief intellectual property lawyer, Roy F. Waldron, testified before a House trade subcommittee hearing on US-India trade relations that India’s stance makes it extremely difficult to get and keep a medicine patent there.

“We have seen several countries adopt policies similar to India’s, which are leading to a worldwide deteriorating trend” that weakens the competitiveness of US drugmakers and threatens U.S. economic growth and future medical advances, Waldron said.

But some say ending research in India would backfire, or that operating in India is so cheap a pullout wouldn’t make sense.

“That would just be cutting off their nose to spite their face,” said analyst Steve Brozak of WBB Securities, adding, “It’s still much cheaper to put whole lab in India,” as opposed to hiring a postdoctoral student to do research in the US.

Your Thoughts …
Linda A. Johnson

Linda A. Johnson

Similar Picks:

Exodus: Tens of Thousands Flee as Myanmar Junta Troops Face Last Stand in Kokang
Burma

Exodus: Tens of Thousands Flee as Myanmar Junta Troops Face Last Stand in Kokang

by Hein Htoo Zan
November 28, 2023
98.5k

Myanmar National Democratic Alliance Army troops are opening roads and pathways through forests for people to flee Kokang’s capital as...

Read moreDetails
Burning Alive in Myanmar: Two Resistance Fighters Executed in Public
Burma

Burning Alive in Myanmar: Two Resistance Fighters Executed in Public

by The Irrawaddy
February 7, 2024
89.9k

People’s Defense Force says junta troops told every household in the village to send one member to witness the double...

Read moreDetails
Another Entire Junta Battalion Raises the White Flag in Myanmar’s Northern Shan State
War Against the Junta

Another Entire Junta Battalion Raises the White Flag in Myanmar’s Northern Shan State

by The Irrawaddy
November 29, 2023
87.1k

Brotherhood Alliance member says it now has complete control of Kokang’s northernmost section after the junta’s Light Infantry Battalion 125...

Read moreDetails
Depleted Myanmar Military Urges Deserters to Return to Barracks
Burma

Depleted Myanmar Military Urges Deserters to Return to Barracks

by The Irrawaddy
December 4, 2023
59k

The junta said deserters would not be punished for minor crimes, highlighting the military’s shortage of troops as resistance offensives...

Read moreDetails
As Myanmar’s Military Stumbles, a Top General’s Dissapearance Fuels Intrigue
Burma

As Myanmar’s Military Stumbles, a Top General’s Dissapearance Fuels Intrigue

by The Irrawaddy
April 19, 2024
47k

The junta’s No. 2 has not been seen in public since April 3, sparking rumors that he was either gravely...

Read moreDetails
Enter the Dragon, Exit the Junta: Myanmar’s Brotherhood Alliance makes Chinese New Year Vow
Burma

Enter the Dragon, Exit the Junta: Myanmar’s Brotherhood Alliance makes Chinese New Year Vow

by The Irrawaddy
February 12, 2024
44.8k

Ethnic armed grouping says it will continue Operation 1027 offensive until goal of ousting the junta is achieved. 

Read moreDetails
Load More
Next Post

Former Chalabi Aide Says Iran ‘Chief Supporter’ of Rohingya

Ancient Stolen Buddha Returned to Burma After 25 Years

No Result
View All Result

Recommended

‘Reforms Are Not Optional’: Prominent Activist Urges NUG to Act Before It’s Too Late

‘Reforms Are Not Optional’: Prominent Activist Urges NUG to Act Before It’s Too Late

2 days ago
995
Trump’s Tariffs to Hit Myanmar’s Garment Manufacturers Hard

Trump’s Tariffs to Hit Myanmar’s Garment Manufacturers Hard

3 days ago
991

Most Read

  • Chinese Investment Reshapes Myanmar’s N. Shan as MNDAA Consolidates Power

    Chinese Investment Reshapes Myanmar’s N. Shan as MNDAA Consolidates Power

    shares
    Share 0 Tweet 0
  • Myanmar Junta Deploying Conscripts in Major Push to Reclaim Lost Territory

    shares
    Share 0 Tweet 0
  • Myanmar Junta Chief Thanks Trump for Shutting Down VOA and RFA

    shares
    Share 0 Tweet 0
  • KIA Denies Rumor Chief Under House Arrest in China

    shares
    Share 0 Tweet 0
  • Two Prominent Myanmar Ex-Political Prisoners Die Hours Apart in Yangon

    shares
    Share 0 Tweet 0

Newsletter

Get The Irrawaddy’s latest news, analyses and opinion pieces on Myanmar in your inbox.

Subscribe here for daily updates.

Contents

  • News
  • Politics
  • War Against the Junta
  • Myanmar’s Crisis & the World
  • Conflicts In Numbers
  • Junta Crony
  • Ethnic Issues
  • Asia
  • World
  • Business
  • Economy
  • Election 2020
  • Elections in History
  • Cartoons
  • Features
  • Opinion
  • Editorial
  • Commentary
  • Guest Column
  • Analysis
  • Letters
  • In Person
  • Interview
  • Profile
  • Dateline
  • Specials
  • Myanmar Diary
  • Women & Gender
  • Places in History
  • On This Day
  • From the Archive
  • Myanmar & COVID-19
  • Intelligence
  • Myanmar-China Watch
  • Lifestyle
  • Travel
  • Food
  • Fashion & Design
  • Videos
  • Photos
  • Photo Essay
  • Donation

About The Irrawaddy

Founded in 1993 by a group of Myanmar journalists living in exile in Thailand, The Irrawaddy is a leading source of reliable news, information, and analysis on Burma/Myanmar and the Southeast Asian region. From its inception, The Irrawaddy has been an independent news media group, unaffiliated with any political party, organization or government. We believe that media must be free and independent and we strive to preserve press freedom.

  • Copyright
  • Code of Ethics
  • Privacy Policy
  • Team
  • About Us
  • Careers
  • Contact
  • Burmese

© 2023 Irrawaddy Publishing Group. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Burma
    • Politics
    • World
    • Asia
    • Myanmar’s Crisis & the World
    • Ethnic Issues
    • War Against the Junta
    • Junta Cronies
    • Conflicts In Numbers
    • Junta Watch
    • Fact Check
    • Investigation
    • Myanmar-China Watch
    • Obituaries
  • Politics
  • Opinion
    • Commentary
    • Guest Column
    • Analysis
    • Editorial
    • Stories That Shaped Us
    • Letters
  • Ethnic Issues
  • War Against the Junta
  • In Person
    • Interview
    • Profile
  • Business
    • Economy
    • Business Roundup
  • Books
  • Donation

© 2023 Irrawaddy Publishing Group. All Rights Reserved

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.